Cystoid Macular Oedema (CME) and Immune Responses after DMEK/Triple DMEK: Real Life Data from Oregis

Abstract

Background Oregis is the multi-centre registry of the German Ophthalmological Society, that systematically collects a comprehensive data set on ophthalmological care in Germany. Here we present the first analysis of Descemet Membrane Endothelial Keratoplastic (DMEK). Only two of the following centres provided the data presented here, but, in the future, participation in Oregis will increase so that data from different eye hospitals and clinics and outpatient and inpatient treatments will be covered.

Objectives Overview of real-life care after DMEK in Germany.

Methods The data was analysed using SweetVIZ 2.1.4. SweetViz is an open-source Python library for automated exploratory data analysis (EDA). Statistical tests were performed using R.

Results Cystoid macular oedema (CME) and immune response are significant complications of DMEK, and both are treated by corticosteroids.

Discussion The future expansion of the register will provide data on the current situation and indicate possible improvements in postoperative care in Germany.

Conclusion Box

Already known:

• DMEK is the gold standard for corneal endothelial disease.

• CME and IR are possible complications of DMEK.

• Postoperative controls are preventive because early treatment is possible.

Newly described:

• Presentation of the first comprehensive evaluation of Oregis data on the care situation after DMEK in Germany.

• The data set is currently very small, but in the future there is the potential for analyses with high data counts through the Oregis network.

Fazit

Bereits bekannt:

• DMEK ist der Goldstandard für korneale Endothelerkrankungen.

• CMÖ und IR sind mögliche Komplikationen der DMEK.

• Postoperative Kontrollen wirken präventiv, da eine frühzeitige Behandlung möglich ist.

Neu beschrieben:

• Darstellung der ersten flächendeckenden Auswertung von Oregis-Daten über die Versorgungslage nach DMEK in Deutschland.

• Bisher sehr kleiner Datensatz, aber in Zukunft Potenzial für Analysen mit hohen Datenzahlen durch das Oregis-Netzwerk möglich.

Keywords

registry - DMEK - CME - Oregis - immune reaction - corticoid therapy

Publication History

Received: 28 February 2025

Accepted: 07 July 2025

Accepted Manuscript online:
08 July 2025

Article published online:
25 September 2025

• References/Literatur

• 1 Storp JJ, Dicke C, Böhringer D. et al. [oregis-The German ophthalmological registry]. Ophthalmologie 2023; 120: 717-725
• 2 Howaldt A, Clahsen T, Mestanoglu M. et al. [Pathogenesis of Fuchs endothelial corneal dystrophy, the fibrillar layer and individualized treatment]. Ophthalmologie 2024; 121: 787-795
• 3 Flockerzi E, Turner C, Seitz B. et al. Descemetʼs membrane endothelial keratoplasty is the predominant keratoplasty procedure in Germany since 2016: a report of the DOG-section cornea and its keratoplasty registry. Br J Ophthalmol 2024; 108: 646-653
• 4 Schaub F, Bachmann BO, Cursiefen C. et al. Midterm follow-up of immune reactions after Descemet membrane endothelial keratoplasty (DMEK). Graefes Arch Clin Exp Ophthalmol 2019; 257: 1811-1812
• 5 Hos D, Tuac O, Schaub F. et al. Incidence and Clinical Course of Immune Reactions after Descemet Membrane Endothelial Keratoplasty: Retrospective Analysis of 1000 Consecutive Eyes. Ophthalmology 2017; 124: 512-518
• 6 Anshu A, Price MO, Tan DT. et al. Endothelial keratoplasty: a revolution in evolution. Surv Ophthalmol 2012; 57: 236-252
• 7 Gurnani B, Kaur K, Lalgudi VG. et al. Risk Factors for Descemet Membrane Endothelial Keratoplasty Rejection: Current Perspectives-Systematic Review. Clin Ophthalmol 2023; 17: 421-440
• 8 Kocaba V, Mouchel R, Fleury J. et al. Incidence of Cystoid Macular Edema After Descemet Membrane Endothelial Keratoplasty. Cornea 2018; 37: 277-282
• 9 Mao Y, Gao LQ, Jia LY. et al. Observation of the Curative Effect of the Dexamethasone Vitreous Cavity Implant for the Treatment of Irvine-Gass Syndrome. Biomed Environ Sci 2023; 36: 725-731
• 10 Obis J, Arias L, Lorenzo D. et al. Topical NSAIDs, intravitreal dexamethasone and peribulbar triamcinolone for pseudophakic macular edema. BMC Ophthalmol 2021; 21: 387
• 11 Fuhrmann L, Böhringer D, Gass P. et al. [Current situation of electronic medical records in ophthalmological departments in Germany]. Ophthalmologie 2022; 119: 827-833
• 12 Schrittenlocher S, Schaub F, Hos D. et al. Evolution of Consecutive Descemet Membrane Endothelial Keratoplasty Outcomes Throughout a 5-Year Period Performed by Two Experienced Surgeons. Am J Ophthalmol 2018; 190: 171-178
• 13 Siebelmann S, Kolb K, Scholz P. et al. The Cologne rebubbling study: a reappraisal of 624 rebubblings after Descemet membrane endothelial keratoplasty. Br J Ophthalmol 2021; 105: 1082-1086
• 14 Thygesen LC, Ersbøll AK. When the entire population is the sample: strengths and limitations in register-based epidemiology. Eur J Epidemiol 2014; 29: 551-558
• 15 Young A, Dixey J, Williams P. et al. An evaluation of the strengths and weaknesses of a register of newly diagnosed rheumatoid arthritis, 1986–2010. Rheumatology (Oxford) 2011; 50: 176-183